Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SELEXIPAG vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Treatment of pulmonary arterial hypertension (PAH; WHO Group I) to improve exercise capacity and delay clinical worsening.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal elimination half-life is approximately 6–8 hours following intravenous administration; with oral administration, the effective half-life is ~6–9 hours due to enterohepatic recirculation; clinical context: dosing every 6 hours is required to maintain therapeutic plasma concentrations.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Primarily metabolized by CYP2C8 and CYP3A4; minor contribution from UGT1A3, UGT2B7, and CYP2C9.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily hepatic metabolism (approximately 97% of dose) via CYP2C8 and CYP3A4; biliary/fecal excretion of metabolites accounts for ~77% of total clearance; renal excretion <1% as unchanged drug.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Approximately 99% bound to plasma proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
Volume of distribution at steady state is approximately 1.7 L/kg (range 1.1–2.5 L/kg), indicating extensive extravascular distribution.
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral bioavailability is approximately 90% under fed conditions; absorption is delayed and reduced by high-fat meals, but overall systemic exposure is increased by ~30% compared to fasting.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <15 m L/min/1.73 m²) or on dialysis; use with caution.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce starting dose to 200 mcg once daily and titrate cautiously; monitor closely.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Not approved for pediatric use; safety and efficacy not established.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
No specific dose adjustment recommended; initiate at 200 mcg twice daily and titrate based on tolerability, considering increased sensitivity and comorbidities.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh class C).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Elderly patients may have increased exposure.,Patients with hepatic impairment: dose adjustment required for moderate impairment; avoid in severe impairment.,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases selexipag exposure by 11-fold; reduce dose.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) reduces exposure; monitor efficacy.,May cause headache, diarrhea, jaw pain, flushing, and nausea.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Severe hepatic impairment (Child-Pugh class C).,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil).
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Take with food to improve tolerance. Avoid grapefruit and grapefruit juice as they may increase selexipag plasma concentrations. No other significant food interactions known.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP receptor agonist), risk of fetal harm cannot be excluded, particularly in the first trimester.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
No data on selexipag in human milk. In animal studies, selexipag is excreted in rat milk. M/P ratio unknown. Breastfeeding is not recommended during treatment and for at least 7 days after last dose.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Selexipag is not recommended in pregnancy. No dose adjustment data exist; pharmacokinetics in pregnancy have not been studied. Theoretical changes in volume of distribution and hepatic clearance may require monitoring, but no specific adjustments are established.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Selexipag is a prostacyclin receptor (IP receptor) agonist used for pulmonary arterial hypertension (PAH). It is a prodrug that requires hepatic carboxylesterase 1 (CES1) activation. Monitor for signs of pulmonary edema suggestive of pulmonary veno-occlusive disease. Concurrent use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases exposure and is contraindicated. Dose adjustment needed in moderate hepatic impairment (Child-Pugh B). Thyroid abnormalities and bleeding risk are potential concerns.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take selexipag exactly as prescribed, typically twice daily with food to reduce gastrointestinal side effects.,Do not crush or chew tablets; swallow whole.,Common side effects include headache, diarrhea, nausea, jaw pain, and muscle aches; report persistent or severe symptoms.,Avoid grapefruit juice as it may increase drug levels.,Inform your doctor if you experience signs of bleeding (unusual bruising, nosebleeds) or thyroid issues (fatigue, weight changes).,Do not stop abruptly without medical advice; sudden discontinuation may worsen PAH.,If you are taking gemfibrozil or other CYP2C8 inhibitors, discuss with your doctor as combination is contraindicated.,Women of childbearing potential should use effective contraception; discuss pregnancy planning with your doctor.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
"Hydrochlorothiazide, a thiazide diuretic, reduces blood pressure primarily by decreasing plasma volume and cardiac output, while Selexipag, a prostacyclin receptor agonist, causes vasodilation and inhibits platelet aggregation. Their concomitant use results in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope. This interaction is particularly significant in patients with compromised baroreflex function or those receiving other antihypertensives."
"Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, is primarily metabolized by CYP2C8 and CYP3A4. Abiraterone, a CYP3A4 inhibitor, may reduce the clearance of selexipag, leading to increased selexipag exposure. This can potentiate its adverse effects such as headache, flushing, and hypotension, though the impact on abiraterone levels is minimal due to abiraterone's multiple metabolic pathways."
"Bretylium, an antiarrhythmic agent, exerts sympatholytic effects by blocking norepinephrine release from adrenergic nerve terminals, leading to peripheral vasodilation and potential hypotension. Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, also induces vasodilation via activation of IP receptors in vascular smooth muscle. When coadministered, the vasodilatory effects are additive, increasing the risk of clinically significant hypotension, which may manifest as dizziness, syncope, or impaired organ perfusion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SELEXIPAG vs OFIRMEV, answered by our medical review team.
SELEXIPAG is a Prostacyclin Receptor Agonist that works by Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SELEXIPAG and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SELEXIPAG is: Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SELEXIPAG and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SELEXIPAG is classified as Category C. Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP recept. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.